NCT05641324 2024-02-12
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Anaveon AG
Phase 1 Terminated
Anaveon AG
Medical Enterprises Ltd.
Cellectar Biosciences, Inc.
Precision Therapeutics